百利天恒：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序

Core Viewpoint - Bailitianheng (688506.SH) announced that its self-developed, first-in-class, new concept, and the only EGFR×HER3 dual-target ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Group 1 - The drug iza-bren is the first EGFR×HER3 dual-target ADC globally to be included in the priority review list [1]